They are in accordance with recently published data indicating a dominant-negative effect of missense TP53 mutations rather than acquisition of novel oncogenic properties in myeloid malignancies based on in vitro and in vivo analyses, as well as clinical data [45]. This evidence concerns the gene TP53 and myeloid neoplasm.